Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New Corporate Tax Law To Change Medical Industry Landscape

This article was originally published in PharmAsia News

Executive Summary

China's new corporate income tax law, which came into effect in 2008, seeks to lower corporate income tax for companies that qualify as high-tech enterprises. To encourage more technology investment, corporate R&D expenses will receive 150 percent deduction before taxation. Revenue from the commercialization or transfer of technology will be tax-exempted for the first 5 million yuan, with taxation halved for the balance. To remove the difference in taxation for local and foreign firms, now at 33 percent and 18 percent respectively, the new law will standardize the rate at 25 percent. Foreign pharmaceutical companies will be taxed 18 percent this year, 20 percent in 2009, 22 percent in 2010, 24 percent in 2011, and 25 percent from 2012. (Click here for more - Chinese Language)
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC067807

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel